Skip to content

Advertisement

  • Poster presentation
  • Open Access

The paediatric hepatic international tumour trial (PHITT): clinical trial design in rare disease

  • Veronica Moroz1,
  • Bruce Morland2,
  • Gregory Tiao3,
  • Eiso Hiyama4,
  • Pamela Kearns1 and
  • Keith Wheatley1
Trials201516(Suppl 2):P224

https://doi.org/10.1186/1745-6215-16-S2-P224

Published: 16 November 2015

Keywords

Liver CancerPaediatric CancerHepatoblastomaClinical Trial DesignPosterior Probability Distribution

Hepatoblastoma is a comparatively uncommon paediatric solid tumour, while hepatocellular carcinoma is very rare.

The Paediatric Hepatic International Tumour Trial will be the single largest clinical trial undertaken in paediatric liver cancer patients as collaboration between the European Study Group for Paediatric Liver Tumours, Children’s Oncology Group and Japanese Study Group for Pediatric Liver Tumors.

In the context of the low incidence paediatric cancer, an overarching study with therapeutic questions for the separate tumour types and risk groups will be more efficient than setting up separate studies for each group. Hence, the design will incorporate randomised comparisons for five different patient groups. It is difficult to obtain feasible sample sizes based on conventional frequentist design criteria. Therefore, Bayesian methods based on probability distributions will be used with event-free survival as the primary outcome measure for each comparison summarised by hazard ratio. Posterior probability distributions, with non-informative priors, based on the number of events will be used to give probabilities of one treatment being better than another. Operating characteristics are explored through simulations of various scenarios given pre-specified decision criteria. The level of evidence needed will depend on the clinical question: for example, a stronger level of evidence is likely to be needed if treatment is being intensified than if two regimens of comparable intensity are being compared.

It is important to investigate promising approaches in randomised trials. The design will enable quicker and more efficient identification of effective therapies, leading to improved outcomes for children with liver cancer.

Authors’ Affiliations

(1)
University of Birmingham, Birmingham, UK
(2)
Birmingham Children’s Hospital NHS Trust, Birmingham, UK
(3)
UC Department of Surgery, Cincinnati, USA
(4)
Hiroshima University Hospital, Hiroshima, Japan

Copyright

© Moroz et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement